Sign up to save your podcasts
Or
Share HCC: Current State, Available and Emerging Therapies – Episode 1
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
HCC: Current State, Available and Emerging Therapies – Episode 1
In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.
View all episodes
By Practicing Clinicians Exchange
4.2
66 ratings
In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.